Zoledronic Acid 5Mg/Bag 100Ml Inj

DRUG4 trials

Sponsors

Hamad Medical Corporation, California Pacific Medical Center Research Institute, Australian and New Zealand Intensive Care Research Centre, Lene Bergendal Solberg

Conditions

Atypical ParkinsonismCritical IllnessDementia With Lewy BodiesHip FracturesMultiple System AtrophyOsteoporosisParkinson DiseaseParkinson's Disease and Parkinsonism

Phase 2

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

RecruitingNCT04608630

Australian and New Zealand Intensive Care Research CentreCritical Illness, Osteoporosis

Start: 2021-07-15End: 2027-02-28Target: 450Updated: 2026-03-04

Phase 3

Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

TerminatedNCT03040765

Hamad Medical CorporationOsteoporosis, Thalassemia Majors (Beta-Thalassemia Major)

Start: 2018-05-14End: 2019-04-08Updated: 2019-12-12

Phase 4

Trial of Parkinson's And Zoledronic Acid

CompletedNCT03924414

California Pacific Medical Center Research InstituteAtypical Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy +6

Start: 2019-11-15End: 2026-02-28Updated: 2026-06-25

Zoledronate Early to Hip Fracture Patients - Safe and Effective?

CompletedNCT05025293

Lene Bergendal SolbergHip Fractures, Osteoporosis

Start: 2021-12-15End: 2026-06-11Updated: 2026-08-12

Related Papers

The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism

npj Parkinson s Disease2021-03-0125 citations